sb-01 peptide YH14618 (coded SB-01 by Spine - Vicatertidepeptide SB-01 is a 7-amino acid synthetic peptide SB-01 Peptide: Unpacking a Novel Therapeutic Approach for Degenerative Disc Disease

Vicatertidepeptide The landscape of pain management and tissue regeneration is constantly evolving, with researchers exploring innovative compounds to address chronic conditions. Among these emerging agents is the sb-01 peptide, a synthetic molecule garnering significant attention, primarily for its potential in treating chronic low back pain (CLBP) associated with degenerative disc disease (DDD). This article delves into the scientific underpinnings of the sb-01 peptide, its mechanism of action, clinical development, and the current understanding of its efficacy and safety.

At its core, sb-01 peptide is described as a synthetic 7-amino acid peptide. This specific amino acid sequence is designed to interact with and modulate key biological pathways involved in inflammation and tissue repair. A central aspect of its proposed therapeutic action is its ability to bind to and antagonize transforming growth factor beta 1 (TGF-β1).2025年8月4日—Known also as Remedisc or vicatertide,SB-01 is a synthetic 7-amino acid peptidedesigned to target transforming growth factor beta 1, or TGFβ1, ... TGF-β1 is a pleiotropic cytokine, meaning it exerts a wide range of effects throughout the body, and is known to play a significant role in fibrotic processes and inflammation, which are implicated in the progression of DDD. By inhibiting TGF-β1 activity, the sb-01 peptide aims to reduce the inflammatory cascade and potentially promote a more favorable environment for tissue healing within the intervertebral discs.

The development of the sb-01 peptide has been spearheaded by Spine BioPharma, with the compound also being investigated under the name vicatertide.Spine BioPharma Announces First Patient Treated in U.S. ... This vicatertide is a TGF beta-1 inhibitor that has undergone rigorous clinical investigation2025年8月4日—Its lead candidate, SB‑01 (vicatertide), isa synthetic peptidedesigned to reduce inflammation and support tissue repair by modulating TGF .... The primary focus of these trials has been to confirm the safety and effectiveness of SB-01 For Injection in adult patients suffering from chronic low back pain and the associated disability. The strategic delivery of sb-01 injection is intended to target the affected spinal discs directly, optimizing its therapeutic impact.

In the realm of clinical research, Spine BioPharma's Phase III MODEL trial assessing SB-01 for individuals with CLBP linked to DDD has been a pivotal undertakingSpine BioPharma Announces First Patient Treated in U.S. .... This large-scale study aimed to evaluate the compound's potential as a first-in-class intradiscal pharmacologic treatment for CLBP management and its impact on functional limitations. While acknowledging that the SB-01 demonstrated durable clinical improvements and consistent results, it's important to note that the trial did not achieve its primary endpointSpine BioPharma concludes enrolment in Phase III back .... This outcome, reported in August 2025, underscores the complexities of clinical trials and the nuances of therapeutic development.Vicatertide (SB-01) | TGF beta-1 Inhibitor However, the pursuit of understanding the sb-01 peptide continues, with researchers examining the data to glean further insights.

The investigation into the sb-01 peptide extends beyond its application in DDD. The underlying mechanism of modulating growth factors has implications in various regenerative medicine contextsSpine BioPharma, Inc. Announces Agreement with Ensol .... While not directly related to the primary use of sb-01 peptide, understanding the broader scientific landscape of peptides is crucial.Moderate - Severe Degenerative Disc Disease Evaluation ... For instance, research into compounds like SBP1 is a 23 amino acid fragment of the ACE2 peptidase domain (PD) α1 helix highlights the diverse roles peptides can play in biological interactions, such as in the context of viral binding.SB-01 is a peptide administered by an injection into the spinal disc. Possible benefits include the reduction of pain-related disability associated with ... Similarly, understanding the structure of MBP-B (84-102) DRB1*15:01, a component of myelin basic protein, or the function of Influenza hemagglutinin is a glycoprotein found on the surface of influenza viruses, demonstrates that peptides are fundamental building blocks with multifaceted biological significance. These examples, while distinct from sb-01 peptide, illustrate the complexity and potential of peptide-based therapeutics and diagnostics.

Despite the mixed results from the primary endpoint of the Phase III trial, the exploration of sb-01 peptide represents a significant step in developing novel treatments for debilitating pain conditions. The commitment from entities like Spine BioPharma and their collaborations, such as with Ensol BioSciences, indicate ongoing interest and investment in this therapeutic avenueSpine BioPharma Announces Topline Results from Phase 3 .... The journey of YH14618 (coded SB-01 by Spine), a 7-amino acid peptide that binds to and induces down-regulation of transforming growth, signifies the ongoing scientific endeavor to refine and understand its potential.Spine BioPharma Announces Topline Results from Phase ... The potential for sb-01 for sale or that sb-01 peptide for sale remains a point of interest for researchers and clinicians globally, though availability is currently tied to research and clinical trial contexts. The research into whether sb-01 peptide may help treat chronic low back pain caused by Degenerative Disc Disease is ongoing, with further analysis of the MODEL trial data expected to provide more clarity.

In summary, the sb-01 peptide, also known as vicatertide, is a synthetic 7-amino acid peptide developed by Spine BioPharma as a potential treatment for degenerative disc disease.2025年8月1日—SB-01 is a 7-amino acid synthetic peptidethat binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by ... Its mechanism of action involves antagonizing TGF-β1, a key inflammatory mediator. While a significant Phase III trial did not meet its primary objective, the sb-01 peptide has shown promise in demonstrating durable clinical benefits. The scientific community continues to investigate its potential, recognizing the intricate role of peptides in biological processes and the ongoing need for effective therapeutic solutions for chronic pain conditions.